TrialInternational journal of molecular sciences2021

Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.

Robin Reschke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.